Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multi-Institutional Phase I/II Study of Revlimid (Lenalidomide), Velcade (Bortezomib), Dexamethasone, and Doxil, (RVDD) Combination Therapy for Patients With Newly Diagnosed Multiple Myeloma.

Next Previous
Trial Profile

A Multi-Institutional Phase I/II Study of Revlimid (Lenalidomide), Velcade (Bortezomib), Dexamethasone, and Doxil, (RVDD) Combination Therapy for Patients With Newly Diagnosed Multiple Myeloma.

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 15 Jan 2019

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Most Recent Events

  • 03 May 2017 Status changed from active, no longer recruiting to completed.
  • 01 Jun 2009 Results were presented at the American Society of Clinical Oncology (ASCO) Annual Meeting, according to a Millennium media release.
  • 27 May 2009 Additional lead trial investigators identified as reported by ClinicalTrials.gov record.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top